LY3537031
Sponsors
Eli Lilly and Company
Conditions
Alcohol Use DisorderConstipationDiarrheaEnd Stage Renal Disease (ESRD)HealthyHepatic InsufficiencyIrritable Bowel SyndromeObesity
Phase 1
A Study of LY3537031 in Healthy Participants
CompletedNCT04648865
Start: 2020-12-09End: 2021-06-04Updated: 2021-06-21
A Study of LY3537031 in Overweight, Obese, and Healthy Participants
Active, not recruitingNCT06606106
Start: 2024-09-05End: 2026-07-01Target: 302Updated: 2026-01-20
A Study of the Pharmacokinetics and Safety of LY3537031 in Participants With Normal Liver Function and With Mild, Moderate, or Severe Liver Impairment
RecruitingNCT07165002
Start: 2025-10-20End: 2026-08-31Target: 32Updated: 2025-12-04
A Study of Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal Impairment
CompletedNCT07165015
Start: 2025-09-18End: 2026-04-16Updated: 2026-04-24
A Study of How the Body Absorbs LY3537031
CompletedNCT07202871
Start: 2025-11-03End: 2026-07-17Updated: 2026-07-23
Phase 2
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)
RecruitingNCT07545759
Start: 2026-05-06End: 2027-11-01Target: 531Updated: 2026-09-17
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)
RecruitingNCT07545772
Start: 2026-04-29End: 2027-09-01Target: 342Updated: 2026-09-17
Phase 3
A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder
RecruitingNCT07219966
Start: 2025-10-15End: 2028-04-01Target: 1100Updated: 2026-09-04
A Study of Brenipatide in Participants With Alcohol Use Disorder
RecruitingNCT07219953
Start: 2025-10-16End: 2028-04-01Target: 1100Updated: 2026-08-21